Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Danazol
Drug ID BADD_D00576
Description A synthetic steroid with antigonadotropic and anti-estrogenic activities that acts as an anterior pituitary suppressant by inhibiting the pituitary output of gonadotropins. It possesses some androgenic properties. Danazol has been used in the treatment of endometriosis and some benign breast disorders.
Indications and Usage For the treatment of endometriosis and fibrocystic breast disease (in patients unresponsive to simple measures). Also used for the prophylactic treatment of all types of hereditary angioedema in males and females.
Marketing Status Prescription; Discontinued
ATC Code G03XA01
DrugBank ID DB01406
KEGG ID D00289
MeSH ID D003613
PubChem ID 28417
TTD Drug ID D09IPV
NDC Product Code 0527-1392; 53104-7501; 49076-5201; 0527-1369; 71052-662; 62991-2832; 42291-243; 0555-0635; 0555-0633; 38779-0174; 49452-2436; 0555-0634; 0527-1368; 71205-861; 71205-862
Synonyms Danazol | Danazant | Panacrine | Danocrine | Ladogal | Cyclomen | Danatrol | Danol | Danoval | Norciden | Azol | Danazol-Ratiopharm | Danazol Ratiopharm
Chemical Information
Molecular Formula C22H27NO2
CAS Registry Number 17230-88-5
SMILES CC12CCC3C(C1CCC2(C#C)O)CCC4=CC5=C(CC34C)C=NO5
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
ThrombophlebitisProtein kinase C delta typeQ05655T448613840287; 2363094; 8800154; 2146406
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Tachycardia02.03.02.007--Not Available
Tension19.06.02.005--Not Available
Testicular atrophy21.13.01.001; 05.05.02.004--Not Available
Thrombocytopenia01.08.01.002--Not Available
Thrombosis24.01.01.006--Not Available
Tremor17.01.06.002--
Urticaria23.04.02.001; 10.01.06.001--
Vertigo17.02.12.002; 04.04.01.003--
Vision blurred17.17.01.010; 06.02.06.007--
Visual impairment06.02.06.0080.010820%Not Available
Vomiting07.01.07.0030.002823%
Vulvovaginal discomfort21.08.02.005--Not Available
Vulvovaginal dryness21.08.02.003--
Weight increased13.15.01.0060.010820%
Thyroxin binding globulin abnormal13.10.06.013--Not Available
Acute coronary syndrome24.04.04.011; 02.02.02.015--Not Available
Platelet count increased13.01.04.002--Not Available
Musculoskeletal discomfort15.03.04.001--Not Available
Lipoprotein (a) abnormal13.12.01.016--Not Available
Nodule08.03.05.002--Not Available
Affect lability19.04.01.001--Not Available
Haemorrhage24.07.01.002--Not Available
Blood alkaline phosphatase increased13.04.02.0040.002823%
Sex hormone binding globulin13.10.05.016--Not Available
Hepatic enzyme increased13.03.01.0190.010820%Not Available
Appetite disorder19.09.01.002; 14.03.01.004--Not Available
Hyperinsulinism14.06.03.007; 05.06.03.007--Not Available
Libido disorder21.03.02.006; 19.08.03.004--Not Available
Joint lock15.01.08.004--Not Available
Decreased appetite08.01.09.028; 14.03.01.0050.002823%
The 5th Page    First    Pre   5 6    Next   Last    Total 6 Pages